Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces it has led, alongside CDP Venture Capital as co-lead investor, a €12 million follow-on investment in Serenis, a pioneer and one of the fastest growing companies dedicated to improving access to mental health and wellbeing services in Italy.
Health Technology Insights: Novartis to Launch Direct-to-Patient Platform for Cosentyx in the US
Founded in 2021 by Silvia Wang and Daniele Francescon, Serenis has rapidly grown into one of the leading platforms for mental and physical wellbeing in Europe. Today, the company has built a network of over 2,500 licensed professionals – including psychotherapists, psychiatrists, nutritionists, and coaches – and has supported more than 170,000 people with around 1.5 million completed therapy sessions. The team has expanded to 65 employees, and serves more than 250 companies, reaching over 300,000 employees through corporate wellbeing programs with clients such as Nestlé, Satispay, Leroy Merlin, and Q8. This strong traction translated into revenues growing from €2M in 2022 to €25M in 2024, with a run-rate already above €40M in 2025.
Health Technology Insights: CareCloud Acquires HFMA’s MAP App to Boost AI Benchmarking
Serenis’ hybrid model connects people with qualified therapists through proprietary digital technology, tackling accessibility barriers and the stigma that often surround mental health disorders. This investment will accelerate Serenis’ innovation in digital care services, strengthen its proprietary technologies and expand its leadership in delivering transformative solutions to corporate clients.
At Angelini Ventures, mental health and brain health are a core priority. Building on investments in innovative therapeutics for depression, epilepsy, and Alzheimer’s disease, as well as in medtech solutions such as devices for epilepsy, Angelini Ventures is committed to supporting advances that can transform care. The investment in Serenis reflects this focus and underscores the firm’s belief that improving mental and brain health is essential to addressing some of the most pressing current healthcare challenges.
Elia Stupka, Managing Director of Angelini Ventures and board member of Serenis since its first financing round, said “We are proud to have believed in Serenis since its early steps and to accompany its growth today as lead investor. Investing in Serenis means believing that mental and physical wellbeing should be accessible to everyone. At Angelini Ventures, we are honored to support a team that, with clinical rigor and innovation, is building an accessible and sustainable model of digital and in-person care, set to become a benchmark in Italy.”
Silvia Wang, Founder of Serenis, added “Innovation in digital mental health depends on ambitious entrepreneurial initiatives, and this milestone highlights both the growth we have achieved and the potential for further expansion ahead.”
Health Technology Insights: Neura Health Raises $11.4 Million to Expand Neurology Care Nationwide
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
